Skip to main content

Table 1 Studying demographic data, liver, and renal profile among studied groups

From: The role of IL-4 gene polymorphism in HCV-related hepatocellular carcinoma in Egyptian patients

  Control
(n = 30)
Cirrhosis
(n = 40)
HCC
(n = 50)
p value
Age (years)
 Median (range)
50.00 (40.00–59.00) 52.5 (43.00–66.00) 52.5 (42.00–67.00) 0.066
Gender
 Male (n, %)
 Female (n, %)
16 (53.3)
14 (46.7)
22 (55.0)
18 (45.0)
32 (64.0)
18 (36.0)
0.562
ALT (U/L)
Median (range)
17.00 (9.0–36.0) 48.50 (16.0–146.0) 55.50 (20.0–102.0) < 0.001 a,b
AST (U/L)
 Median (range)
19.00 (9.0–36.0) 60.50 (16.0–146.0) 62.50 (20.0–102.0) < 0.001 a,b
Total bilirubin (mg/dL)
 Median (range)
0.50 (0.10–0.80) 1.19 (0.45–4.18) 1.50 (0.73–3.63) < 0.001 a,b
Direct bilirubin (mg/dL)
 Median (range)
0.10 (0.07–0.23) 0.38 (0.09–3.08) 0.62 (0.18–2.53) < 0.001 a,b
Albumin (g/dL)
 Median (range)
4.40 (3.50–5.10) 3.68 (2.20–4.90) 3.32 (2.20–4.52) < 0.001 a,b
Urea (mg/dL)
 Median (range)
27.50 (17.0–41.0) 37.50 (22.0–56.0) 38.00 (22.0–67.0) < 0.001 a,b
Creatinine (mg/dL)
 Median (range)
0.80 (0.50–1.20) 0.87 (0.58–1.50) 1.00 (0.50–1.50) 0.001 a,b
  1. ALT alanine aminotransferase, AST aspartate aminotransferase
  2. Data are median and range in parenthesis, otherwise are n (%)
  3. Significant p value < 0.05
  4. aOn comparing a control and cirrhotic patients
  5. bControl and HCC patients
  6. cCirrhotic and HCC patients